With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of Latin America remains uncertain.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on New York Times.